Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $17.47 Analyst target: $33.81 Upside: 93.53%
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.
See the full interactive analysis & chart →Informational only — not investment advice.